? Animal Core-001 Age-related hearing loss (ARHL) ? presbycusis ? is a significant Public Health issue and the number one communication disorder and neurodegenerative condition of our aged population; and ranks as one of the top three chronic medical conditions, along with arthritis and cardiovascular diseases. Although much has been learned, the search is on for biomedical treatments that prevent, slow down or reverse the consequences of ARHL. In fact, there are no FDA-approved drugs to treat sensorineural hearing loss, despite a prevalence of over 40 million people in the US alone. Furthermore, approximately 30% of those listeners complain of tinnitus, i.e., sound perception in the absence of acoustic stimulation. The scope of the Animal Core will support the other projects to delineate the functional effects on neural correlates of complex sound processing using different modulators of presbycusis. More specifically, Core-001 (Animal Core) of this Program Project is responsible for obtaining, maintaining, and aging mice and rats; and in a timely manner provides experimental subjects for Projects 2-4 and Core-002. As such, the Animal Core is organized to achieve the following objectives: Purchase and maintain breeding colonies of mice and rats; To raise healthy animals in an optimal environment for research on the aging auditory system; To perform special procedures such as identification tagging and tattooing, diagnostic audiometry, obtaining tissue samples and gathering baseline information from animals; Perform diagnostic auditory brainstem response (ABR) audiometry to establish the hearing thresholds of subjects before (both acute and longitudinal) and during (longitudinal) experiments; and to maintain a secure database of vital information about colony animals, including birth dates, lineage, ABR audiometry test dates and results, and an experimental procedure log.
- Animal Core - 001 Presbycusis, or Age -Related Hearing Loss (ARHL), is the number one communication disorder and number one neurodegenerative condition of our expanding aging population; and comprises one of the top 3 chronic medical conditions, along with arthritis and cardiovascular diseases. The vast majority of people over age 60 are affected by this progressive decline in auditory sensitivity and speech understanding, which are hallmarks of ARHL. Despite this high prevalence of ARHL, there currently are no medical treatments for preventing or reversing permanent hearing loss (ARHL or other types). The thematic focus of this proposal is modulation of presbycusis through biotherapeutics and acoustic treatments. If the experiments proposed here to test hypotheses concerning interventions to modulate the progression of presbycusis are successful, the novel results should lead to clinical trials of the efficacy of these innovative technological, acoustic and drug-related treatments.
Showing the most recent 10 out of 123 publications
